{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:35:46Z","timestamp":1792067746202,"version":"4.4.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"The OSUCCC Drug Development Institute"},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OSU CCC and Division of Hematology start-up funds"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA252469"],"award-info":[{"award-number":["R01CA252469"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01HL163849"],"award-info":[{"award-number":["R01HL163849"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Cancer Society Research Scholar","award":["RSG-22-053-01-IBCD"],"award-info":[{"award-number":["RSG-22-053-01-IBCD"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32CA090223"],"award-info":[{"award-number":["T32CA090223"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ohio State University Comprehensive Cancer Center"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute graft-versus-host disease (GVHD) is a donor T cell driven complication and the leading cause of non-relapse mortality in patients receiving an allogeneic hematopoietic cell transplantation (allo-HCT). Allogeneic donor T cells eradicate residual leukemia and prevent relapse via the graft-versus-leukemia (GVL) effect and are critical for responding against opportunistic infections post-transplant. Current regimens successful in preventing GVHD are broadly immunosuppressive and come at the cost of increased risk of relapse and\/or infection. Therefore, there is an urgent need for new approaches that limit GVHD while retaining GVL responses.<\/jats:p>\n               <jats:p>During GVHD, alloreactive T cells boost their energy production through oxidative phosphorylation (OXPHOS) and glycolysis, supporting heightened proliferation and pathogenicity against healthy host tissues. The enzyme dihydroorate dehydrogenase (DHODH), is essential for de novo pyrimidine biosynthesis and for maintaining mitochondrial membrane potential during OXPHOS. Having shown upregulation of DHODH messenger RNA and protein expression in activated human T cells, we evaluated DHODH inhibition, via a small molecule inhibitor HOSU-53, as a therapeutic approach for GVHD. Inhibiting DHODH significantly reduced oxidative metabolism in T cells both during and after activation, while selectively suppressing inflammatory cytokine production in de novo activated, but not previously activated, T cells. In a xenogeneic model, HOSU-53 treatment limited GVHD severity, decreased pathogenic Th1 and Th17 response, and preserved beneficial GVL effects. Altogether, we identify DHODH inhibition as an innovative treatment strategy in allo-HCT recipients to reduce GVHD severity and retain effective GVL response.<\/jats:p>","DOI":"10.1093\/jimmun\/vkaf023","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T11:27:44Z","timestamp":1742729264000},"page":"818-827","source":"Crossref","is-referenced-by-count":3,"title":["DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-<\/i>host disease while retaining <i>graft-<\/i>versus<i>-<\/i>leukemia response"],"prefix":"10.1093","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4693-8319","authenticated-orcid":false,"given":"Rathan","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1145-1053","authenticated-orcid":false,"given":"Kara M","family":"Braunreiter","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8156-0100","authenticated-orcid":false,"given":"Lotus","family":"Neidemire-Colley","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Sell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandi","family":"Gao","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camryn","family":"Steere","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruva","family":"Vanakeri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Michael E. DeBakey VA Medical Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2849-2989","authenticated-orcid":false,"given":"Hannah K","family":"Choe","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Vibhute","sequence":"additional","affiliation":[{"name":"Drug Discovery Shared Resource, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Bennett","sequence":"additional","affiliation":[{"name":"Drug Discovery Shared Resource, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]},{"name":"Drug Development Institute, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A","family":"Byersdorfer","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota , Minneapolis, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola A","family":"Elgamal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Hendrix College , Conway, AR,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K","family":"Hertlein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Byrd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathi","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"2025043003515857300_vkaf023-B1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematology (United States)"},{"key":"2025043003515857300_vkaf023-B2","author":"Auletta","year":"2021"},{"key":"2025043003515857300_vkaf023-B3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrclinonc.2014.102","article-title":"Current and emerging strategies for the prevention of graft-versus-host disease","volume":"11","author":"Choi","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2025043003515857300_vkaf023-B4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2014-01-514786","article-title":"Acute graft-versus-host disease: a bench-to-bedside update","volume":"124","author":"Holtan","year":"2014","journal-title":"Blood"},{"key":"2025043003515857300_vkaf023-B5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajh.25355","article-title":"Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission","volume":"94","author":"Poir\u00e9","year":"2019","journal-title":"Am J Hematol"},{"key":"2025043003515857300_vkaf023-B6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-pathol-020117-043720","article-title":"New insights into graft-versus-host disease and graft rejection","volume":"13","author":"Perkey","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"2025043003515857300_vkaf023-B7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149296","article-title":"Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease","volume":"131","author":"Soci\u00e9","year":"2021","journal-title":"J Clin Invest"},{"key":"2025043003515857300_vkaf023-B8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2017.00496","article-title":"Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia","volume":"8","author":"Dickinson","year":"2017","journal-title":"Front Immunol"},{"key":"2025043003515857300_vkaf023-B9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.25.022106.141606","article-title":"Immunobiology of allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Welniak","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"2025043003515857300_vkaf023-B10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.21873\/anticanres.11483","article-title":"Acute graft versus host disease: a comprehensive review","volume":"37","author":"Nassereddine","year":"2017","journal-title":"Anticancer Res"},{"key":"2025043003515857300_vkaf023-B11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood.2019004271","article-title":"Introduction to a review series on pathophysiology and treatment of acute GVHD","volume":"136","author":"Zeiser","year":"2020","journal-title":"Blood"},{"key":"2025043003515857300_vkaf023-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2025043003515857300_vkaf023-B13","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"2025043003515857300_vkaf023-B14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2016.01.012","article-title":"Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions","volume":"22","author":"Kumar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025043003515857300_vkaf023-B15","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/0008-5472.CAN-16-1311","article-title":"Allogeneic stem cell transplantation: a historical and scientific overview","volume":"76","author":"Singh","year":"2016","journal-title":"Cancer Res"},{"key":"2025043003515857300_vkaf023-B16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2023020073","article-title":"Novel developments in the prophylaxis and treatment of acute GVHD","volume":"142","author":"Jamy","year":"2023","journal-title":"Blood"},{"key":"2025043003515857300_vkaf023-B17","doi-asserted-by":"crossref","first-page":"605726","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD Prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"key":"2025043003515857300_vkaf023-B18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood.2023020035","article-title":"Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events","volume":"142","author":"Takahashi","year":"2023","journal-title":"Blood"},{"key":"2025043003515857300_vkaf023-B19","doi-asserted-by":"crossref","first-page":"1057694","DOI":"10.3389\/fimmu.2022.1057694","article-title":"Controversies and expectations for the prevention of GVHD: A biological and clinical perspective","volume":"13","author":"Watkins","year":"2022","journal-title":"Front Immunol"},{"key":"2025043003515857300_vkaf023-B20","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin","year":"2021","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025043003515857300_vkaf023-B21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2025043003515857300_vkaf023-B22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"2025043003515857300_vkaf023-B23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"2025043003515857300_vkaf023-B24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Molecular Therapy"},{"key":"2025043003515857300_vkaf023-B25","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed After allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"2025043003515857300_vkaf023-B26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"2025043003515857300_vkaf023-B27","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"key":"2025043003515857300_vkaf023-B28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","article-title":"Targeted disruption of the \u03b2 2-microglobulin gene minimizes the immunogenicity of human embryonic stem cells","volume":"4","author":"Wang","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"2025043003515857300_vkaf023-B29","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(14)71105-2","article-title":"Harnessing GVHD by interleukin-6 receptor blockade","volume":"15","author":"Finke","year":"2014","journal-title":"The Lancet Oncology"},{"key":"2025043003515857300_vkaf023-B30","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.bbmt.2017.05.001","article-title":"Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease","volume":"23","author":"Yalniz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025043003515857300_vkaf023-B31","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"2025043003515857300_vkaf023-B32","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"2025043003515857300_vkaf023-B33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/1744666X.2023.2249230","article-title":"Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease","volume":"19","author":"Algeri","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2025043003515857300_vkaf023-B34","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood-2014-06-577023","article-title":"Phase 3 clinical trial of steroids\/mycophenolate mofetil vs steroids\/placebo as therapy for acute GVHD: BMT CTN 0802","volume":"124","author":"Bola\u00f1os-Meade","year":"2014","journal-title":"Blood"},{"key":"2025043003515857300_vkaf023-B35","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3389\/fimmu.2020.01517","article-title":"Metabolic pathways in alloreactive T cells","volume":"11","author":"Brown","year":"2020","journal-title":"Front Immunol"},{"key":"2025043003515857300_vkaf023-B36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fimmu.2019.00295","article-title":"Metabolic targets for improvement of allogeneic hematopoietic stem cell transplantation and graft-vs.-host disease","volume":"10","author":"Tijaro-Ovalle","year":"2019","journal-title":"Front Immunol"},{"key":"2025043003515857300_vkaf023-B37","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.4049\/jimmunol.1402180","article-title":"Programmed death-1 controls T cell survival by regulating oxidative metabolism","volume":"194","author":"Tkachev","year":"2015","journal-title":"J Immunol"},{"key":"2025043003515857300_vkaf023-B38","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/ni1016-1235b","article-title":"Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease","volume":"17","author":"Mathewson","year":"2016","journal-title":"Nat Immunol"},{"key":"2025043003515857300_vkaf023-B39","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/bloodadvances.2023010740","article-title":"AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease","volume":"8","author":"Ramgopal","year":"2024","journal-title":"Blood Adv"},{"key":"2025043003515857300_vkaf023-B40","doi-asserted-by":"crossref","first-page":"751296","DOI":"10.3389\/fimmu.2022.751296","article-title":"Targeting glycolysis in alloreactive T cells to prevent acute graft-versus-host disease while preserving graft-versus-leukemia effect","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"2025043003515857300_vkaf023-B41","doi-asserted-by":"crossref","first-page":"67ra8","DOI":"10.1126\/scitranslmed.3001975","article-title":"Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease","volume":"3","author":"Gatza","year":"2011","journal-title":"Sci Transl Med"},{"key":"2025043003515857300_vkaf023-B42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.immuni.2012.10.020","article-title":"Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling","volume":"38","author":"Sena","year":"2013","journal-title":"Immunity"},{"key":"2025043003515857300_vkaf023-B43","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.cmet.2017.05.007","article-title":"Cytochrome c oxidase activity is a metabolic checkpoint that regulates cell fate decisions during T cell activation and differentiation","volume":"25","author":"Tarasenko","year":"2017","journal-title":"Cell Metab"},{"key":"2025043003515857300_vkaf023-B44","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.immuni.2017.02.010","article-title":"Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation","volume":"46","author":"Tan","year":"2017","journal-title":"Immunity"},{"key":"2025043003515857300_vkaf023-B45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","article-title":"Mitochondrial dynamics controls T cell fate through metabolic programming","volume":"166","author":"Buck","year":"2016","journal-title":"Cell"},{"key":"2025043003515857300_vkaf023-B46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-immunol-101819-082015","article-title":"Mitochondrial metabolism regulation of T cell-mediated immunity","volume":"39","author":"Steinert","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"2025043003515857300_vkaf023-B47","doi-asserted-by":"crossref","first-page":"102129","DOI":"10.1016\/j.msard.2020.102129","article-title":"Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis","volume":"43","author":"Muehler","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025043003515857300_vkaf023-B48","doi-asserted-by":"crossref","first-page":"2040622320944773","DOI":"10.1177\/2040622320944773","article-title":"Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations","volume":"11","author":"Malla","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"2025043003515857300_vkaf023-B49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12974-018-1110-z","article-title":"Teriflunomide promotes oligodendroglial differentiation and myelination","volume":"15","author":"G\u00f6ttle","year":"2018","journal-title":"J Neuroinflammation"},{"key":"2025043003515857300_vkaf023-B50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14728222.2018.1536748","article-title":"The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia","volume":"22","author":"Sykes","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"2025043003515857300_vkaf023-B51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/scitranslmed.aao5563","article-title":"Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects","volume":"11","author":"Klotz","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025043003515857300_vkaf023-B52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173646","article-title":"Pyrimidine depletion enhances targeted and immunotherapy combinations in 1 acute myeloid leukemia","volume":"9","author":"Elgamal","year":"2024","journal-title":"JCI Insight"},{"key":"2025043003515857300_vkaf023-B53","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: 1. The roles of minor H antigens and endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"2025043003515857300_vkaf023-B54","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010570","article-title":"CRISPR\/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model","volume":"8","author":"Neidemire-Colley","year":"2024","journal-title":"Blood Adv"},{"key":"2025043003515857300_vkaf023-B55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","article-title":"Adaptive linear step-up procedures that control the false discovery rate","volume":"93","author":"Benjamini","year":"2006","journal-title":"Biometrika"},{"key":"2025043003515857300_vkaf023-B56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbmt.2005.10.012","article-title":"Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation","volume":"12","author":"Nieto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025043003515857300_vkaf023-B57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025043003515857300_vkaf023-B58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"2025043003515857300_vkaf023-B59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","article-title":"Memory CD4+ T cells do not induce graft-versus-host disease","volume":"112","author":"Anderson","year":"2003","journal-title":"J Clin Invest"},{"key":"2025043003515857300_vkaf023-B60","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.4049\/jimmunol.0802212","article-title":"Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia","volume":"182","author":"Zheng","year":"2009","journal-title":"J Immunol"},{"key":"2025043003515857300_vkaf023-B61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41590-023-01436-x","article-title":"Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development","volume":"24","author":"Scherer","year":"2023","journal-title":"Nat Immunol"},{"key":"2025043003515857300_vkaf023-B62","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3389\/fimmu.2019.02839","article-title":"Metabolic pathways involved in regulatory T cell functionality","volume":"10","author":"Kempkes","year":"2019","journal-title":"Front Immunol"},{"key":"2025043003515857300_vkaf023-B63","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J Immunol"},{"key":"2025043003515857300_vkaf023-B64","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.coi.2010.01.018","article-title":"Metabolism in T cell activation and differentiation","volume":"22","author":"Pearce","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"2025043003515857300_vkaf023-B65","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165723","article-title":"Donor T cell STAT3 deficiency enables tissue PD-L1\u2013dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Invest"},{"key":"2025043003515857300_vkaf023-B66","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"JCO"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/4\/818\/62522623\/vkaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/4\/818\/62522623\/vkaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:52:21Z","timestamp":1745999541000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/214\/4\/818\/8090295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkaf023","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,22]]}}}